Compare AD & MMSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AD | MMSI |
|---|---|---|
| Founded | 1983 | 1987 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Medical/Dental Instruments |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.3B | 4.8B |
| IPO Year | N/A | 1990 |
| Metric | AD | MMSI |
|---|---|---|
| Price | $50.07 | $83.25 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 8 |
| Target Price | $51.67 | ★ $105.38 |
| AVG Volume (30 Days) | 192.2K | ★ 618.0K |
| Earning Date | 11-07-2025 | 10-30-2025 |
| Dividend Yield | ★ 45.87% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | 0.18 | ★ 1.95 |
| Revenue | ★ $3,795,787,000.00 | $1,477,128,000.00 |
| Revenue This Year | N/A | $13.53 |
| Revenue Next Year | $28.22 | $6.30 |
| P/E Ratio | $278.49 | ★ $43.09 |
| Revenue Growth | ★ 252.49 | 11.41 |
| 52 Week Low | $44.03 | $78.12 |
| 52 Week High | $79.17 | $111.45 |
| Indicator | AD | MMSI |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 41.86 |
| Support Level | N/A | $83.84 |
| Resistance Level | N/A | $88.71 |
| Average True Range (ATR) | 0.00 | 2.04 |
| MACD | 0.00 | -0.45 |
| Stochastic Oscillator | 0.00 | 12.06 |
Array Digital Infrastructure, formerly US Cellular, sold its regional wireless operations serving about 4.4 million customers to T-Mobile in August 2025. The firm has agreed to sell most of its remaining spectrum licenses to Verizon and AT&T; however, it will still retain rights to C-band spectrum in several locations after these deals are closed. Array also owns a 5.5% stake in Verizon Wireless' Los Angeles operations and about 4,400 wireless towers.
Merit Medical Systems Inc is a medical equipment company that develops and manufactures products for interventional cardiology, radiology, and endoscopy procedures. The firm reports two segments which are Cardiovascular and Endoscopy. The majority of the revenue is earned from the Cardiovascular segment which consists of cardiology and radiology medical device products that assist in diagnosing and treating coronary artery disease, peripheral vascular disease, and other non-vascular diseases and includes embolotherapeutic, cardiac rhythm management, electrophysiology, critical care, and interventional oncology and spine devices.